Search results for "triple-negative breast cancer"

showing 6 items of 66 documents

Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects

2022

Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging out-comes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are often accompanied by severe side effects. Here, we show that a periodic fasting-mimicking diet (FMD) can act on the tumor microenvironment and increase the efficacy of immunotherapy (anti-PD-L1 and anti-OX40) against the poorly immunogenic triple-negative breast tumors (TNBCs) by expanding early exhausted effector T cells, switching the cancer metabolism from glycolytic to respiratory, and reducing collagen depo-sition. Furthermore, FMD reduces the occurrence of immune-related adve…

Tumor MicroenvironmentHumansTriple Negative Breast NeoplasmsFastingImmunotherapySettore MED/08 - Anatomia PatologicaGlycolysisnutrition triple-negative breast cancer CP: Cancer CP: Immunology fasting fasting-mimicking diet immunotherapy inflammationB7-H1 AntigenGeneral Biochemistry Genetics and Molecular BiologyCell Reports
researchProduct

Synthesis of curcumin derivatives and analysis of their antitumor effects in triple negative breast cancer (TNBC) cell lines

2019

We analyzed antitumor effects of a series of curcumin analogues. Some of them were obtained by reaction of substitution involving the two phenolic OH groups of curcumin while the analogues with a substituent at C-4 was prepared following an original procedure that regards the condensation of benzenesulfenic acid onto the nucleophilic central carbon of the curcumin skeleton. We analyzed cytotoxic effects of such derivatives on two TNBC (triple negative breast cancer) cell lines, SUM 149 and MDA-MB-231, but only three of them showed an IC50 in a lower micromolar range with respect to curcumin. We also focused on these three derivatives that in both cell lines exhibited a higher or at least eq…

antiproliferative activitySubstituentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441antioxidant activityprooxidant activitylcsh:Pharmacy and materia medicapro-apoptotic activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoveryCytotoxic T cellNF-κB inhibitionAntioxidant activity Antiproliferative activity NF-κB inhibition Pro-apoptotic activity Prooxidant activity Sulfenic acidIC50Triple-negative breast cancer030304 developmental biology0303 health sciencesCommunicationlcsh:Rsulfenic acidchemistryCell culture030220 oncology & carcinogenesisCancer researchCurcuminSettore BIO/14 - FarmacologiaMolecular MedicineSulfenic acidLead compound
researchProduct

The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs

2021

Breast cancer (BC) mortality is mainly due to metastatic disease, which is primarily driven by cancer stem cells (CSC). The chemokine C-X-C motif ligand-1 (CXCL1) is involved in BC metastasis, but the question of whether it regulates breast cancer stem cell (BCSC) behavior is yet to be explored. Here, we demonstrate that BCSCs express CXCR2 and produce CXCL1, which stimulates their proliferation and self-renewal, and that CXCL1 blockade inhibits both BCSC proliferation and mammosphere formation efficiency. CXCL1 amplifies its own production and remarkably induces both tumor-promoting and immunosuppressive factors, includingSPP1/OPN,ACKR3/CXCR7,TLR4,TNFSF10/TRAILandCCL18and, to a lesser exte…

breast cancer stem cellsQH301-705.5animal diseasesSettore MED/50 - Scienze Tecniche Mediche ApplicatechemokinesBiologyCXCR4MetastasisCell and Developmental Biologyimmunity geneCancer stem cellmedicinetumor microenvironmentCXC chemokine receptorsBiology (General)immunity genesTriple-negative breast cancerTumor microenvironmentbreast cancer stem cellchemokineCell BiologyBrief Research Reportrespiratory systemmedicine.diseaseCXCL1Tumor progressiontriple-negative breast cancerCancer researchCCL28Settore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Identification and analysis of tumor-associated antigens in triple-negative breast cancer (TNBC)

2020

business.industryCancer researchMedicineIdentification (biology)businessTumor associated antigenTriple-negative breast cancerGeburtshilfe und Frauenheilkunde
researchProduct

Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer

2019

There is still a great unmet medical need concerning diagnosis and treatment of breast cancer which could be addressed by utilizing specific molecular targets. Tumor-associated MUC1 is expressed on over 90 % of all breast cancer entities and differs strongly from its physiological form on epithelial cells, therefore presenting a unique target for breast cancer diagnosis and antibody-mediated immune therapy. Utilizing an anti-tumor vaccine based on a synthetically prepared glycopeptide, we generated a monoclonal antibody (mAb) GGSK-1/30, selectively recognizing human tumor-associated MUC1. This antibody targets exclusively tumor-associated MUC1 in the absence of any binding to MUC1 on health…

medicine.drug_classEstrogen receptorMUC1Breast NeoplasmsMice TransgenicDeferoxamineMonoclonal antibody89Zr03 medical and health sciences0302 clinical medicineBreast cancerIn vivoCell Line TumorBiomarkers TumormedicineAnimalsHumansTissue Distributionskin and connective tissue diseasesMUC1Triple-negative breast cancermAbRadioisotopesMice Inbred BALB Cbiologybusiness.industryMucin-1breast cancer diagnosisAntibodies MonoclonalCancerGeneral MedicinePrognosismedicine.diseaseImmunohistochemistryMice Inbred C57BLPositron-Emission Tomographybiology.proteinCancer researchFemale030211 gastroenterology & hepatologyZirconiumAntibodybusinessResearch PaperInternational Journal of Medical Sciences
researchProduct

(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.

2015

Breast cancer remains the leading cause of cancer-related death among women. The invasive triple-negative subtype is unresponsive to estrogen therapy, and few effective treatments are available. In search of new chemical scaffolds to target this disease, we conducted a phenotypic screen against the human breast carcinoma cell lines MDA-MB-231, MA11, and MCF-7 using terrestrial natural products. Natural products that preferentially inhibited proliferation of triple-negative MDA-MB-231 cells over estrogen receptor-positive cells were further studied; herein we focused on the abietanes. The activity of the abietane carnosol prompted us to generate a focus library from the readily available (+)…

medicine.drug_classPhenotypic screeningApoptosisTriple Negative Breast NeoplasmsPharmacologyCarnosolchemistry.chemical_compoundStructure-Activity RelationshipBreast cancerCell Line TumorDrug DiscoverymedicineHumansTriple-negative breast cancerCell ProliferationPharmacologyBiological ProductsDose-Response Relationship DrugMolecular StructureCell growthDrug discoveryOrganic ChemistryStereoisomerismGeneral MedicineTriple Negative Breast Neoplasmsmedicine.diseaseAntineoplastic Agents PhytogenicchemistryEstrogenAbietanesMCF-7 CellsFemaleDrug Screening Assays AntitumorEuropean journal of medicinal chemistry
researchProduct